Fairfield Bush & CO. Reduces Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fairfield Bush & CO. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 37.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,549 shares of the medical research company’s stock after selling 920 shares during the period. Fairfield Bush & CO.’s holdings in Thermo Fisher Scientific were worth $806,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in TMO. Ally Financial Inc. grew its holdings in shares of Thermo Fisher Scientific by 116.2% in the fourth quarter. Ally Financial Inc. now owns 8,000 shares of the medical research company’s stock valued at $4,162,000 after purchasing an additional 4,300 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $3,650,000. Foster Dykema Cabot & Partners LLC increased its stake in Thermo Fisher Scientific by 5.0% during the fourth quarter. Foster Dykema Cabot & Partners LLC now owns 45,312 shares of the medical research company’s stock worth $23,590,000 after acquiring an additional 2,173 shares during the last quarter. Osterweis Capital Management Inc. raised its holdings in Thermo Fisher Scientific by 2.3% in the 4th quarter. Osterweis Capital Management Inc. now owns 64,286 shares of the medical research company’s stock valued at $33,443,000 after buying an additional 1,419 shares during the period. Finally, Farringdon Capital Ltd. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $548,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research reports. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a research note on Friday, January 31st. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Raymond James reissued an “outperform” rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $647.43.

Get Our Latest Analysis on Thermo Fisher Scientific

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,900 shares of company stock worth $13,106,062. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.9 %

NYSE:TMO opened at $436.90 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $409.85 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a fifty day moving average price of $502.59 and a two-hundred day moving average price of $536.26. The stock has a market capitalization of $164.93 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.